

Pierre Michetti CV and PublicationList

Professional address	Gastroentérologie Beaulieu SA, Centre Crohn et Colite Avenue Jomini 8, CH-1004 Lausanne, Switzerland phone: +41 21-644 3050 Fax: +41 21-644 3059 E-mail: pmichetti@gesb.ch
----------------------	---

Current and Past Hospital Position

Chief physician and director (2009-present)	Gastroentérologie Beaulieu SA, Lausanne
Staff physician (2009-present)	Division of Gastroenterology and Hepatology, CHUV, Lausanne and Clinique La Source, Lausanne
Chief physician (2000-2009)	Division of Gastroenterology and Hepatology, CHUV, Lausanne
Co-Director (1998 to 2000)	Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA
Staff Physician (1996 to 2000)	Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA

Current and Past Academic Appointments

Associate Professor of Gastroenterology (2009-present)	Lausanne University School of Biology and Medicine Lausanne, Switzerland
Vice-Dean (2006-2007)	Lausanne University School of Biology and Medicine Lausanne, Switzerland
Professor of Gastroenterology and Hepatology (2000-2009)	Lausanne University School of Biology and Medicine, Lausanne, Switzerland
Assistant Professor of Medicine (1996-2000)	Harvard Medical School Boston, MA, USA
Privat-Docent in Medicine (1996-2000)	Lausanne University School of Biology and Medicine, Lausanne, Switzerland
Assistant Lecturer in Biochemistry (1988-1990)	Lausanne University School of Biology and Medicine, Lausanne, Switzerland

Awards/Honors

2005	Honor Prize of the Swiss Society of Gastroenterology, Switzerland
1997	FIRST Award, National Institutes of Health (NIH), USA
1997	Basic Research Award, Glaxo-Wellcome Institute for Digestive Health, USA
1994	Honor Prize of the Swiss Society of Gastroenterology Swiss Society of Gastroenterology, Switzerland
1992	Encouragement Award for scientific research Swiss Society of Gastroenterology, Switzerland

Education/Diploma

December 1983	Swiss diploma of Physicians, Lausanne University School of Medicine, Lausanne, Switzerland
April 1988	MD Thesis, Lausanne University School of Medicine Lausanne, Switzerland

July 1989 FMGEMS/ECFMG certificate (Foreign medical graduate Examination in the Medical Sciences), Philadelphia, USA
February 1997 Board certification, FMH in Internal Medicine and subspecialty Gastroenterology, Swiss Federation of Physicians, Bern, Switzerland
March 2000 Principles of Management for Physician Executives, American College of Physician Executives, Tampa, FL, USA

Academic Societies Memberships

1984- Member, Swiss Medical Federation
1990- Member, American Society for Microbiology
1992- Emeritus member, European Helicobacter Pylori Study Group
1996- Member, Swiss Society of Gastroenterology and Hepatology (SSG)
1997- Member, American Gastroenterological Association
2000- Steering committee Member, IBD-net.ch, the Swiss IBD group of SSG
2001- Honorary member, Swiss representative and member of the governing board, scientific officer (2013-2015), and past chairman of the Education Committee (2001-2010), European Crohn's and Colitis Organization (ECCO)
2010-2016 Member, Future Trends Committee, United European Gastroenterology Foundation (UEGF).

Editorial Boards

1994-2007 Current Opinion in Gastroenterology: Co-editor, *The Year in Helicobacter pylori supplement*
1996-2007 *Helicobacter*, Member of the board
2000- Digestive Diseases, Member of the board
2001- Digestive and Liver Diseases, member of the board
2004-2008 Digestion, Associate editor, IBD section

Review boards

American Journal of Gastroenterology
European Journal of Gastroenterology and Hepatology
Current Opinion in Gastroenterology
Gastroenterology
Gut
Helicobacter
Inflammatory Bowel Disease
Infection and Immunity
Journal of Experimental Medicine
Journal of Clinical Investigation
Journal of Crohn's and Colitis
Journal of Immunology
Nature Medicine
New England Journal of Medicine

Institutions

Medical Royal Council, United Kingdom
Swiss National Research Foundation, Switzerland
National Institutes of Health, USA (ad hoc committee)
Irish Medical Council, Ireland
Pasteur Institute Paris, France
Medical Research Council, Australia

PUBLICATION LIST**Original Articles**

1. Michetti P, Berger J-P. Conséquences pratiques des enregistrements ambulatoires de la pression artérielle. *Schweiz Med Wschr* 1989;119:394-398.
2. Weltzin RA, Lucia Jandris P, Michetti P, Fields BN, Kraehenbuhl JP, Neutra MR. Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. *J Cell Biol* 1989;108:1673-1685.
3. Amerongen HM, Weltzin RA, Farnet CM, Michetti P, Haseltine WA, Neutra MR. Transepithelial transport of HIV-1 by intestinal M cells : a mechanism for transmission of AIDS. *J Acquir Immun Defic Syndr* 1991;4:760-765.
4. Michetti P, Mahan MJ, Slauch JM, Mekalanos JJ, Neutra MR. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen *Salmonella typhimurium*. *Infect Immun* 1992;60:1786-1792.
5. Hirt R, Hughes GJ, Frutiger S, Michetti P, Perregaux C, Poulain-Godefroy O, Janguenat N, Neutra MR, Kraehenbuhl JP. Transcytosis of the polymeric Ig receptor requires phosphorylation on Serine 664 in the absence but not the presence of dimeric IgA. *Cell* 1993;74:245-255.
6. Apter FM, Michetti P, Winner LS, Mack JA, Mekalanos JJ, Neutra MR. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against *Vibrio cholerae* and cholera toxin by use of monoclonal IgA antibodies in vivo. *Infect Immun* 1993;61:5279-5285.
7. Michetti P, Porta N, Mahan MJ, Slauch JM, Mekalanos JJ, Blum AL, Kraehenbuhl JP, Neutra MR. Monoclonal IgA prevents adherence and invasion of polarized epithelial cell monolayers by *Salmonella typhimurium*. *Gastroenterology* 1994;107: 915-923. Voir éditorial pp.1193-1195.
8. Phalipon A, Michetti P, Kaufmann M, Cavaillon JM, Huerre M, Kraehenbuhl JP, Sansonetti PJ. Protection against invasion of the mouse pulmonary epithelium by a monoclonal IgA directed against *Shigella flexneri* lipopolysaccharide. *Microb Pathog Immun* 1994;730:356-358.
9. Michetti P, Corthésy-Theulaz I, Davin C, Haas R, Vaney AC, Heitz M, Bille J, Kraehenbuhl JP, Saraga E, Blum AL. Immunization of BALB/c mice against *Helicobacter felis* infection with *Helicobacter pylori* urease. *Gastroenterology* 1994;107: 1002-1011.
10. Slauch JM, Mahan MJ, Michetti P, Neutra MR, Mekalanos JJ. Acetylation (O-factor 5) affects the structural and immunological properties of lipopolysaccharide O antigen. *Infect Immun* 1995;63:437-441.
11. Corthésy-Theulaz I, Porta N, Glauser MH, Saraga E, Vaney AC, Haas R, , Kraehenbuhl JP, Blum AL, Michetti P. Oral immunization with *Helicobacter pylori* urease B as a treatment against *Helicobacter* infection. *Gastroenterology* 1995;109:115-121.
12. Phalipon A, Kaufmann M, Michetti P, Cavaillon JM, Huerre M, Sansonetti P, Kraehenbuhl JP. Monoclonal IgA antibody directed against serotype-specific epitope of *Shigella flexneri* lipopolysaccharide protects against murine experimental shigellosis. *J Exp Med* 1995;182:769-778.
13. Glauser MH, Michetti P, Blum AL, Corthésy-Theulaz I. Carbon 14-urea breath test as a non-invasive method to follow *H. felis* colonisation in mice. *Digestion* 1996;57:30-34.
14. Verdù EF, Fraser R, Tiberio D, Herranz M, Sipponen P, Blum AL, Michetti P. Prevalence of *Helicobacter pylori* infection and chronic dyspeptic symptoms among immigrants from developing countries and people born in industrialized countries. *Digestion* 1996;57:180-185.
15. Kreiss C, Buclin T, Cosma M, Corthésy-Theulaz I, Michetti P. Safety of oral immunisation with recombinant urease against *Helicobacter pylori* infection. *Lancet* 1996;347:1630-1631.
16. Corthésy-Theulaz I, Porta N, Pringault E, Racine L, Bogdanova A, Kraehenbuhl JP, Blum AL, Michetti P. Adhesion of *Helicobacter pylori* to T84 human intestinal cell monolayers is pH-dependent. *Infect Immun* 1996;64:3827-2832.

17. Dorta G, Michetti P, Burckhardt P, Gillet M. Acute ischemia followed by hemorrhagic gastric necrosis after injection sclerotherapy for ulcer. *Endoscopy* 1996;28:532.
18. Wiesel P, Schneider R, Dorta G, Blum AL, Gillet M, Michetti P. Botulinum toxin for post-operative refractory pyloric spasm. *Endoscopy* 1997;29:132.
19. Dorta G, Binek J, Blum AL, Buhler H, Felley CP, Koelz HR, Lammer F, Lang C, Meier R, Meyenberger C, Meyer-Wyss B, Michetti P, Protiva P, Scheurer U, Weber B, Wiesel P, Vogel S. Comparison between esophageal wallstent and ultraflex stents in the treatment of malignant stenoses of the esophagus and cardia. *Endoscopy* 1997;29:149-154.
20. Saldinger PF, Porta N, Launois P, Louis JA, Waanders GA, Blum AL, Michetti P, Corthésy-Theulaz I. Mucosal immunization of BALB/c mice with rUreB induces a T helper type 2 response not seen during infection with *Helicobacter*. *Gastroenterology* 1998;115:891-897.
21. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, Herranz M, Saldinger PF, Corthésy-Theulaz I, Losonsky G, Nichols R, Simon J, Stolte M, Ackerman S, Monath TP, Blum AL. Oral immunization with recombinant urease and *E. coli* heatlabile enterotoxin adjuvant is safe and immunogenic in *H. pylori* infected adults. *Gastroenterology* 1999;116:804-812. Voir éditorial pp.990-994.
22. Michetti P, G. Dorta G, Wiesel PH, Brassart D, E. Verdu H, Herranz M, Felley C, Porta N, Rouvet M, Blum AL, Corthésy-Theulaz I. The effect of whey-based culture supernatant of *Lactobacillus acidophilus* la 1 on *Helicobacter pylori* infection in humans. *Digestion* 1999; 60: 203-209.
23. Farrell RJ, Peppercorn MA, Fine S, Michetti P. Mesalamine-induced thrombocytopenia. *Am J Gastroenterol* 1999; 94: 2304-6.
24. Verdù EF, Bercik P, Cukrowska B, Farré Castany MA, Bouzourene H, Saraga E, Blum AL, Corthésy-Theulaz I, Tlaskalova-Hogenova H, Michetti P. Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in balb/c mice. *Clin Exp Immunol* 2000;120:46-50.
25. Michetti M, Kelly CP, Kraehenbuhl JP, Bouzourene H, Michetti P. Gastric mucosal $\alpha\alpha\alpha\alpha$ integrin-positive lymphocytes and immune protection against helicobacter infection in mice. *Gastroenterology* 2000;119: 109-118.
26. Farrell RJ, Lodhavia P, Shah S, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA. Clinical Experience with Infliximab Therapy in one hundred Crohn's Disease Patients. *Am J Gastro*, 2000;95:3490-7.
27. Greene AK, Michetti P, Peppercorn MA, Hodin, RA. Laparoscopically assisted ileo-colectomy for Crohn's disease through a Pfannenstiel incision. *Am J Surg*. 2000;180:238-40.
28. Felley CP, Corthésy-Theulaz I, Blanco Rivero JL, Sipponen P, Kaufmann D, Bauerfeind P, Brassart D, Pfeifer A, Blum AL, Michetti P. Favorable effect of an acidified milk (LC-1) on *Helicobacter pylori* gastritis in man. *Eur J Gastro Hep*, 2001;13:25-9.
29. Qamar A, Warny M, Michetti P, Pothoulakis C, LaMont JT, Kelly CP. *Saccharomyces boulardii* stimulates an intestinal IgA immune response to *Clostridium difficile* toxin A in mice. *Infect Immun* 2001;69:2762-2765.
30. Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Mach M, Simon J, Kelly CP, Monath TP, Michetti P. Safety and efficacy of low dose *E. coli* enterotoxin adjuvant for urease-based oral immunization against *H. pylori* in healthy volunteers. *Gut* 2002;51:634-40.
31. de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, Mizoguchi E, Metz CN, Sahli MA, ten Hove T, Keates AC, Lubetsky JB, Farrell RJ, Michetti P, van Deventer SJ, Lolis E, David JR, Bhan AK, Terhorst C. Development of chronic colitis is dependent on the cytokine MIF. *Nature Immunol*. 2001 Nov;2(11):1061-6.
32. Mach F, Michetti M, Sukhova GK, Libby P, Michetti P. *Helicobacter pylori* does not influence atherogenesis in LDL receptor-deficient mice. *Circ Res* 2002;90:E1-4.

33. Barcelo-Batllori S, Andre M, Servis C, Levy N, Takikawa O, Michetti P, Reymond M, Felley-Bosco E. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: Implications for inflammatory bowel diseases. *Proteomics*. 2002 ;2:551-60.
34. Fotopoulos G, Harari A, Michetti P, Trono D, Pantaleo G, Kraehenbuhl JP. Transepithelial transport of HIV-1 by M cells is receptor-mediated. *Proc Natl Acad Sci USA* 2002;99:9410-4.
35. Sougioultzis S, Lee CK, Alsahli M, Banerjee S, Cadoz M, Schrader R, Guy B, Bedford Ph, Monath TP, Kelly CP, Michetti P. Safety and efficacy of *E. coli* enterotoxin adjuvant for urease-based rectal immunization against *Helicobacter pylori*. *Vaccine*. 2002 13;21:194-201
36. Felley CP, Pignatelli B, van Melle GD, Crabtree JE, Stolte M, Diezi J, Corthésy-Theulaz I, Michetti P, Bancel B, Patrocot LM, Ahshima H, Felley-Bosco E. Oxidative stress in the gastric mucosa of asymptomatic humans infected with *Helicobacter pylori*: Effect of bacterial eradication. *Helicobacter*. 2002;7:342-8.
37. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces but does not eliminate human anti-chimeric antibodies which are associated with loss of initial response following infliximab therapy. *Gastroenterology*. 2003;124:917-24.
38. Schmidt S, Lepori D, Meuwly JY, Duvoisin B, Meuli R, Michetti P, Felley C, Schnyder P, van Melle G, Denys A. Prospective comparison of MR enteroclysis with multidetector spiral-CT enteroclysis: interobserver agreement and sensitivity by means of "sign-by-sign" correlation. *Eur Radiol*. 2003;13:1303-1
39. Wen S, Felley CP, Bouzourene H, Michetti P, Pan-Hammarström P. Inflammatory gene profiles in gastric mucosa during *Helicobacter pylori* infection in humans. *J Immunol*. 2004;172:2595-606.
40. Delcò F, Michetti P, Beglinger C, Fried M, Szucs TD. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland. *Digestion*. 2004;69:10-9.
41. Felley CP, Michetti P. Engineered lymphocytes to treat dinitrobenzene sulphonic acid colitis in mice. *Eur J Gastroenterol Hepatol*. 2003;15:1253-5.
42. Michetti P. Experimental *Helicobacter pylori* infection in humans: a multifaceted challenge. *Gut*. 2004;53:1220-1.
43. Fried M, Beglinger C, Bobalj NG, Minor N, Coello N, Michetti P; TegaSwiss Study Group. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome. *Eur J Gastroenterol Hepatol*. 2005;17:421-7.
44. Velin D, Bachmann D, Bouzourene H, Michetti P. Mast cells are critical mediators of vaccine-induced *Helicobacter* clearance in the mouse model. *Gastroenterology*. 2005;129:142-55.
45. Anderle P, Rumbo M, Sierro F, Mansourian R, Michetti P, Roberts MA, Kraehenbuhl JP. Novel markers of the human follicle-associated epithelium identified by genomic profiling and microdissection. *Gastroenterology*. 2005;129:321-7.
46. Beglinger C, Thalmann C, Szucs T, Michetti P. Long-term treatment of patients with symptomatic gastroesophageal reflux disease comparing costs and efficacy over 6 months of treatment with Nexium On-Demand Treatment or Nexium continuous treatment. An open, randomised multi-center study. *Schweiz Rundsch Med Prax*. 2006;95:483-7.
47. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. *Gut*. 2006;55 Suppl 1:i36-58.
48. Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, Mottet C, Pittet V, Dubois RW, Wietlisbach V, Michetti P. Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach--EPACT. *Digestion*. 2006;73(4):237-48.

49. Vu F, Maillard M, Pascual M, Michetti P, Felley C. De novo inflammatory bowel diseases after liver transplantation: description of four new cases and a review of the literature. *Gastroenterol Clin Biol.* 2006;30:1096-101.
50. Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P. Infliximab for the Treatment of disseminated Pyoderma Gangrenosum associated with Ulcerative Colitis: A Case Report and Literature Review. *Dermatology,* 2007;215:245-51.
51. Maillard MH, Cotta-de-Almeida V, Takeshima F, Nguyen DD, Michetti P, Nagler C, Bhan AK, Snapper SB. The Wiskott Aldrich Syndrome Protein Is Required For The Function of CD4+CD25+Foxp3+ Regulatory T cells. *Journal of Experimental Medicine* 2007;204:381-91.
52. Wen S, Velin D, Felley CP, Du L, Michetti P, Pan-Hammarström Q. Expression of *Helicobacter pylori* Virulence Factors and Profiles of Associated Inflammatory Gene Expression in the Human Gastric Mucosa. *Infect Immun* 2007;75: 5118-26.
53. Guessous I, Juillerat P, Pittet V, Froehlich F, Burnand B, Mottet C, Felley C, Michetti P, Vader JP. Evaluating Appropriateness of Treatment for Crohn's Disease: Feasibility of an Explicit Approach. *Digestion.* 2007;75:46-52.
54. Lima FS, Simioni S, Bruggimann L, Ruffieux C, Dudler J, Felley C, Michetti P, Annoni JM, Schlupe M. Perceived behavioral changes in early multiple sclerosis. *Behav Neurol.* 2007;18(2):81-90.
55. Juillerat P, Pittet V, Bulliard JL, Antonino AT, Mottet C, Felley CP, Vader JP, Michetti P. Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland): A Population-based Cohort Study. *J Crohn Colitis,* in press.
56. Szucs T, Thalmann C, Michetti P, Beglinger C. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment. An open, randomised multi-centre study in Switzerland. *Value Health.* 2008 Sep 9. [Epub ahead of print]
57. Velin D, Bachmann D, Bouzourene H, Michetti P. Reduction of Helicobacter infection in IL-10-/- mice is dependent on CD4+ T cells but not on mast cells. *Helicobacter.* 2008;13(5):361-9.
58. Juillerat P, Pittet V, Bulliard JL, Guessous I, Antonino AT, Mottet C, Felley C, Vader JP, Michetti P. Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland): A population-based cohort study. *Journal of Crohn's and Colitis* 2008; 2: 131-141.
59. Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, Saiji E, Bouzourene H, Michetti P. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. *Gastroenterology.* 2009;136(7):2237-2246.
60. Bernasconi E, Favre L, Maillard MH, Bachmann D, Pythoud C, Bouzourene H, Croze E, Velichko S, Parkinson J, Michetti P, Velin D. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. *Inflamm Bowel Dis.* 2009 Jul 28. [Epub ahead of print]
61. Nichita C, Abdou AE, Maerten P, Herranz M, Mouret N, Thalmann C, Michetti PF, Dorta G. A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers. *Aliment Pharmacol Ther.* 2009 Nov 15;30(10):1022-9.
62. Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, Michetti P, Vader JP; Swiss IBD Cohort Study Group. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). *Int J Epidemiol.* 2009 Aug;38(4):922-31.
63. Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers JJ, Pittet V, Vader JP, Froehlich F, Felley C, the EPACT II Study Group. Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel—EPACT II. *Journal of Crohn's and Colitis* 2009; 3: 232-240.
64. Felley C, Vader JP, Juillerat P, Pittet V, O'Morain C, Panis Y, Vucelic B, Gonvers JJ, Mottet C, Froehlich F, Michetti P, the EPACT II Study Group. Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel — EPACT II. *Journal of Crohn's and Colitis* 2009; 3: 250-256.

65. Mottet C, Vader JP, Felley C, Froehlich F, Gonvers JJ, Juillerat P, Stockbrügger R, Angelucci E, Seibold F, Michetti P, Pittet V, the EPACT II Study Group. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel—EPACT II. *Journal of Crohn's and Colitis* 2009; 3: 257-263.
66. Juillerat P, Vader JP, Felley C, Pittet V, Gonvers JJ, Mottet C, Bemelman WA, Lémann M, Öresland T, Michetti P, Froehlich F, EPACT II Study Group. Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel — EPACT II. *Journal of Crohn's and Colitis* 2009; 3: 241-249.
67. Schmidt S, Guibal A, Meuwly J-Y, Michetti P, Felley C, Meuli R, Schnyder P, Denys A: Acute Complications of Crohn's Disease: Comparison of Multidetector-Row Computed Tomographic Enterography with Magnetic Resonance Enterography. *Digestion* 2010;82:229-238.
68. Voegtlin M, Vavricka SR, Schoepfer AM, Straumann A, Voegtlin J, Rogler G, Ballabeni P, Pittet V, Buser A, Fried M, Beglinger C; Swiss IBD Cohort Study. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. *J Crohns Colitis*. 2010 Dec;4(6):642-8
69. Juillerat P, Pittet V, Mottet C, Felley C, Gonvers JJ, Vader JP, Burnand B, Froehlich F, Wolters FL, Stockbrügger RW, Michetti P; EC-IBD Group. Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort. *Scand J Gastroenterol* 2010;45:1449-56.
70. Pittet V, Juillerat P, Michetti P, Vader JP, Burnand B, Rogler G, Beglinger C, Seibold F, Mottet C, Felley C, Gonvers JJ, Froehlich F; Swiss IBD Cohort Study Group. Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. *Aliment Pharmacol Ther*. 2010 Oct;32(8):1007-16.
71. Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F; Swiss IBD Cohort Study Group. Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. *Eur J Gastroenterol Hepatol* 2010;22:1352-7.
72. Nichita C, Stelle M, Vavricka S, El-Wafa Ali A, Ballabeni P, de Saussure P, Straumann A, Rogler G, Michetti P. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. *Digestion* 2010;81:78-85.
73. Favre L, Borle F, Velin D, Bachmann D, Bouzourene H, Wagnieres G, van den Bergh H, Ballabeni P, Gabrecht T, Michetti P, Schreiber S, Ortner MA. Low dose endoluminal photodynamic therapy improves murine T cell-mediated colitis. *Endoscopy* 2011;43:604-16.
74. Velin D, Narayan S, Bernasconi E, Busso N, Ramelli G, Maillard MH, Bachmann D, Pythoud C, Bouzourene H, Michetti P, So A. PAR2 promotes vaccine-induced protection against *Helicobacter* infection in mice. *Gastroenterology* 2011;141:1273-82.
75. Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Friedt M, Pittet V; Swiss IBD Cohort Study Group. Epidemiology of inflammatory bowel disease: Is there a shift towards onset at a younger age? *J Pediatr Gastroenterol Nutr*. 2011 Aug;53(2):141-4.
76. Eloranta JJ, Wenger C, Mwinyi J, Hiller C, Gubler C, Vavricka SR, Fried M, Kullak-Ublick GA; Swiss IBD Cohort Study Group. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. *Pharmacogenet Genomics*. 2011 Sep;21(9):559-64.
77. Leblanc S., Allez M., Seksik P., Flourié B., Peeters H., Dupas J.L., Bouguen G., Peyrin-Biroulet L., Duclos B., Bourreille A., Dewit O., Bouhnik Y., Michetti P., Chaussade S., Saussure P., Mary J.Y., Colombel J.F., Lémann M. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis., *American Journal of Gastroenterology* 2011;106 (4):771-777.
78. Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P; Swiss IBDnet. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. *Inflamm Bowel Dis*. 2010;16(6):933-8.

79. Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P; Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. *Inflamm Bowel Dis.* 2011;17(7):1530-9.
80. Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM; Swiss IBD Cohort Study Group. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. *Inflamm Bowel Dis.* 2012;18(3):496-505.
81. Felley C, Bouzourene H, VanMelle MB, Hadengue A, Michetti P, Dorta G, Spahr L, Giostra E, Frossard JL. Age, smoking and overweight contribute to the development of intestinal metaplasia of the cardia. *World J Gastroenterol.* 2012 May 7;18(17):2076-83.
82. Reinisch W, Chowers Y, Danese S, Dignass A, Gomollón F, Nielsen OH, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H. The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method. *Aliment Pharmacol Ther.* 2013;38:1109-18. [PMID: 24099472]
83. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med.* 2013;369:711-21. [PMID: 23964933]
84. Windsor A, Michetti P, Bemelman W, Ghosh S. The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy. *Inflamm Bowel Dis.* 2013;19:2695-703. [PMID:23846487]
85. D'Angelo F, Bernasconi E, Schäfer M, Moyat M, Michetti P, Maillard MH, Velin D. Macrophages promote epithelial repair through hepatocyte growth factor secretion. *Clin Exp Immunol.* 2013;174:60-72. [PMID:23773083]
86. Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; Swiss Inflammatory Bowel Disease Cohort Study Group. Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease. *Digestion.* 2013;87:212-21. [PMID:23711401]
87. Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A; EPACK-II Update Panellists. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. *J Crohns Colitis.* 2013;7:820-6. [PMID:23664620]
88. Sulz MC, Siebert U, Arvandi M, Gothe RM, Wurm J, von Känel R, Vavricka SR, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group. Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study. *Eur J Gastroenterol Hepatol.* 2013;25:790-7. [PMID:23571609]
89. Siebert U, Wurm J, Gothe RM, Arvandi M, Vavricka SR, von Känel R, Bégré S, Sulz MC, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group. Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study. *Inflamm Bowel Dis.* 2013;19:847-55. PMID:23446333]
90. Pittet V, Rogler G, Mottet C, Froehlich F, Michetti P, de Saussure P, Burnand B, Vader JP; the Swiss IBD Cohort Study Group*. Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients. *Scand J Gastroenterol.* 2014;49(6):662-73.

91. Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Peyrin-Biroulet L, Michetti P, Rogler G, Vavricka SR; IBD Cohort Study Group. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. *Am J Gastroenterol*. 2013 Nov;108(11):1744-53
92. Maillard MH, Bega H, Uhlig HH, Barnich N, Grandjean T, Chamailard M, Michetti P, Velin D. Toll-interacting Protein Modulates Colitis Susceptibility in Mice. *Inflamm Bowel Dis*. 2014 Apr;20(4):660-70.
93. Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V; The Swiss IBD Cohort Study Group. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. *J Crohns Colitis*. 2014.
94. Pittet V, Maillard MH, Lauvergeon S, Timmer M, Michetti P, Froehlich F, Burnand B, Vader JP, Mottet C. Acceptance of inflammatory bowel disease treatment recommendations based on appropriateness ratings: do practicing gastroenterologists agree with experts? *J Crohns Colitis*. 2014 Dec 9.
95. Bernasconi E, D'Angelo F, Michetti P, Velin D. Critical Role of the GM-CSF Signaling Pathway in Macrophage Pro-Repair Activities. *Pathobiology*. 2014;81(4):183-9.
96. Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. Addressing current treatment challenges in Crohn's disease in real life: A physician's survey. *Dig Liver Dis*. 2014 Dec;46(12):1066-71.
97. Schoepfer AM, Bortolotti M, Pittet V, Mottet C, Gonvers JJ, Reich O, Fournier N, Vader JP, Burnand B, Michetti P, Froehlich F. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease. *Aliment Pharmacol Ther*. 2014 Oct;40(8):930-7.
98. Hiroz P, Vavricka SR, Fournier N, Safroneeva E, Pittet V, Rogler G, Schoepfer AM and Swiss Inflammatory Bowel Diseases Cohort Study Group. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. *Scand J Gastroenterol*. 2014 Oct;49(10):1207-18.
99. Violi NV, Schoepfer AM, Fournier N, Guiu B, Bize P, Denys A; Swiss Inflammatory Bowel Disease Cohort Study Group. Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss Inflammatory Bowel Disease Cohort. *AJR Am J Roentgenol*. 2014 Jul;203(1):62-9. Erratum in: *AJR Am J Roentgenol*. 2014 Aug;203(2):463.
100. Schaffer T, Schoepfer AM, Seibold F; Swiss IBD Cohort Study Group. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity. *J Crohns Colitis*. 2014 Sep 1;8(9):1125-32.
101. Danese S, Fiorino G, Michetti P. Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. *J Crohns Colitis*. 2014 Nov 1;8(11):1548-50.
102. Multone E, Vader JP, Mottet C, Schoepfer A, Fournier N, Burnand B, Michetti P, Pittet V. Characteristics of non-responders to self-reported questionnaires in a large inflammatory bowel disease cohort study. *Scand J Gastroenterol*. 2015 Apr 28;1-9.
103. Ditisheim S, Fournier N, Juillerat P, Pittet V, Michetti P, Gabay C, Finckh A; Swiss IBD Cohort Study Group. Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study. *Inflamm Bowel Dis*. 2015 Nov;21(11):2598-604.
104. Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. *Aliment Pharmacol Ther*. 2015 Oct;42(8):977-89.

105. Safroneeva E, Vavricka S, Fournier N, Seibold F, Mottet C, Nydegger A, Ezri J, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. *Aliment Pharmacol Ther.* 2015 Sep;42(5):540-8
106. Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. *Inflamm Bowel Dis.* 2015 Aug;21(8):1794-800
107. Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. *Gastroenterology.* 2016;150(2):380-388.
108. Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Cosnes J, Allez M, Duclos B, Grimaud JC, Bommelaer G, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, and Pariente B. Efficacy and safety of subcutaneous ustekinumab in refractory Crohn's disease: a multicenter retrospective study. *Clin Gastroenterol Hepatol.* 2016;14(2):242-250.
109. Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A, Aubourg A, Fumery M, Altwegg R, Michetti P, Chanteloup E, Seksik P, Baudry C, Flamant M, Bouguen G, Stefanescu C, Bourrier A, Bommelaer G, Dib N, Bigard MA, Viennot S, Hébuterne X, Gornet JM, Marteau P, Bouhnik Y, Abitbol V, Nahon S; GETAID. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. *J Crohns Colitis.* 2016;10(10):1179-85.
110. Pittet V, Vaucher C, Maillard MH, Girardin M, de Saussure P, Burnand B, Rogler G, Michetti P. Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort? *PLoS One.* 2016 Mar 3;11(3).
111. Vaucher C, Maillard MH, Froehlich F, Burnand B, Michetti P, Pittet V. Patients and gastroenterologists' perceptions of treatments for inflammatory bowel diseases: do their perspectives match? *Scand J Gastroenterol.* 2016;51(9):1056-61.
112. Mikocka-Walus A, Pittet V, Rossel JB, von Känel R; Swiss IBD Cohort Study Group. Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol.* 2016;14(6):829-835.
113. Michetti P. A Look Beyond the Biosimilarity of the Molecules. *J Crohns Colitis.* 2016;10(2):123-4.
114. Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study. Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way? *J Crohns Colitis.* 2016 Mar;10(3):269-76.
115. Danese S, Fiorino G, Michetti P. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. *J Crohns Colitis.* 2016 Nov;10(11):1362-1365.
116. Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-Brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2016;22(11):2733-2747.
117. Pittet V, Vaucher C, Froehlich F, Burnand B, Michetti P, Maillard MH; Swiss IBD Cohort Study Group. Patient self-reported concerns in inflammatory bowel diseases: A gender-specific subjective quality-of-life indicator. *PLoS One.* 2017 Feb 10;12(2).
118. Michetti P, Weinman J, Mrowietz U, Smolen J, Peyrin-Biroulet L, Louis E, Schremmer D, Tundia N, Nurwakagari P, Selenko-Gebauer N. Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. *Adv Ther.* 2017;34(1):91-108.

119. Rouiller-Braunschweig C, Fournier N, Pittet V, Dudler J, Michetti P. Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients. *Digestion*. 2017 Oct 24;96(4):220-227.
120. Pepe J, Zawadzynski S, Herrmann FR, Juillerat P, Michetti P, Ferrari-Lacraz S, Belli D, Ratib O, Rizzoli R, Chevalley T, Ferrari SL. Structural Basis of Bone Fragility in Young Subjects with Inflammatory Bowel Disease: A High-resolution pQCT Study of the SWISS IBD Cohort (SIBDC). *Inflamm Bowel Dis*. 2017 Aug;23(8):1410-1417.
121. Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflamm Bowel Dis*. 2017 Jul;23(7):1174-1181.
122. Michetti P. Efficacy of infliximab biosimilars in patients with Crohn's disease. *Lancet*. 2017 Dec 2;390(10111):2435.
123. Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; Swiss IBD Cohort Study Group. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. *Eur J Gastroenterol Hepatol*. 2018;30(6):612-620.
124. Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Serrero M, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). *Aliment Pharmacol Ther*. 2018;47(5):588-595.
125. Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, Zimmerli L, Vavricka SR, Rogler G, Scharl M; Swiss IBD Cohort Study Group. *Inflamm Bowel Dis*. 2018 Apr 13. doi: 10.1093/ibd/izy054. [Epub ahead of print].
126. Lang BM, Biedermann L, van Haaften WT, de Vallière C, Schuurmans M, Begré S, Zeitz J, Scharl M, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerwinkel N, Misselwitz B; Swiss IBD Cohort Study Group. Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease. *Aliment Pharmacol Ther*. 2018;47(1):55-66.
127. Pittet V, Vaucher C, Froehlich F, Maillard MH, Michetti P; Swiss IBD Cohort Study Group. Patient-reported healthcare expectations in inflammatory bowel diseases. *PLoS One*. 2018 May 17;13(5):e0197351.
128. Safroneeva E, Saner C, Rossel JB, Golay D, Pittet V, Godat S, Diem S, Aepli P, Sawatzki M, Borovicka J, Burgmann K, Juillerat P, Netzer P, Sendensky A, Hruz P, Girardin M, Biedermann L, Greuter T, Vavricka S, Michetti P, Mueller C, Straumann A, Schoepfer AM; Swiss EoE Cohort Study Group. Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECs). *Inflamm Intest Dis*. 2018 Mar;2(3):163-170. doi: 10.1159/000486131. Epub 2018 Jan 3.
129. Kolios AGA, Hueber AJ, Michetti P, Mrowietz U, Mustak-Blagusz M, Sator PG, Reinshagen M, Wilsmann-Theis D, Gomis-Kleindienst S, Luckey U, Rössler A, Schiefke I. ALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN study. *J Eur Acad Dermatol Venereol*. 2018 Jul 12. doi: 10.1111/jdv.15179.
130. Pittet V, Maillard MH, Simonson T, Fournier N, Rogler G, Michetti P. Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals *Clin Gastroenterol Hepatol*. 2018 Nov 21. pii: S1542-3565(18)31272-2. doi: 10.1016/j.cgh.2018.11.029. [Epub ahead of print]
131. Rivière P, Münch A, Michetti P, Chande N, de Hertogh G, Schoeters P, Ferrante M, Vermeire S, Van Assche G. Vedolizumab in refractory microscopic colitis: an international case series. *J Crohns Colitis*. 2018 Oct 17. doi: 10.1093/ecco-jcc/jjy169. [Epub ahead of print]

132. Tcymbarevich IV, Eloranta JJ, Rossel JB, Obialo N, Spalinger M, Cosin-Roger J, Lang S, Kullak-Ublick GA, Wagner CA, Scharl M, Seuwen K, Ruiz PA, Rogler G, de Vallière C, Misselwitz B; Swiss IBD Cohort Study Group. The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation. *BMC Gastroenterol.* 2019 Jan 7;19(1):2. doi: 10.1186/s12876-018-0922-8.
133. Pittet V, Michetti P, Mueller C, Braegger CP, von Känel R, Schoepfer A, Macpherson AJ, Rogler G. Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). *Int J Epidemiol.* 2019 Jan 27. doi: 10.1093/ije/dyy298. [Epub ahead of print]
134. Yilmaz B, Juillerat P, Øyås O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M, Pittet VEH, Maillard MH, Rogler G; Swiss IBD Cohort Investigators, Wiest R, Stelling J, Macpherson AJ. Microbial network disturbances in relapsing refractory Crohn's disease. *Nat Med.* 2019 Feb;25(2):323-336. doi: 10.1038/s41591-018-0308-z. Epub 2019 Jan 21. Erratum in: *Nat Med.* 2019 Apr;25(4):701.
135. Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist CA, Posfay-Barbe KM; Swiss Inflammatory Bowel Disease Cohort Study Group. High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. *Am J Gastroenterol.* 2019 Jul;114(7):1130-1141.
136. Pillai N, Lupatsch JE, Dusheiko M, Schwenkglens M, Maillard M, Sutherland CS, Pittet VEH; Swiss IBD Cohort Study group. Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data. *J Crohns Colitis.* 2020 May 21;14(4):490-500.
137. Cernoch PS, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group. Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. *Dig Dis Sci.* 2020 Sep;65(9):2654-2663. doi: 10.1007/s10620-019-05978-9.
138. Schreiner P, Rossel JB, Biedermann L, Valko PO, Baumann CR, Greuter T, Scharl M, Vavricka SR, Pittet V, Juillerat P, Rogler G, von Känel R, Misselwitz B; Swiss IBD Cohort Study Group. Fatigue in inflammatory bowel disease and its impact on daily activities. *Aliment Pharmacol Ther.* 2020 Nov 7. doi: 10.1111/apt.16145.
139. Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. *United European Gastroenterol J.* 2020 Nov 17;2050640620965106. doi: 10.1177/2050640620965106

Reviews, Editorials, Book chapters

140. Neutra MR, Weltzin RA, Winner LSI, Mack J, Michetti P, Morrison LA, Fields BN, Mekalanos JJ, Kraehenbuhl JP. Identification and use of protective monoclonal IgA antibodies against viral and bacterial pathogens. *Adv Exp Med Biol* 1991;310: 186-189.
141. Michetti P, Hirt R, Weltzin RA, Fasel N, Schaerer E, Neutra MR, Kraehenbuhl JP. Production and use of monoclonal IgA antibodies complexed with recombinant secretory component for passive mucosal protection. In Mestecky J. , ed. *Immunology of milk and the neonate*. New York: Plenum press, 1991: 183-185.
142. Michetti P, Blum AL, Kraehenbuhl JP. A la recherche d'un vaccin. *UNI Lausanne.* 1992;70: 44-49.
143. Michetti P, Gonvers JJ. Biologie moléculaire en gastro-entérologie clinique. *Méd & Hyg.* 1992; 50: 184-192.
144. Kraehenbuhl JP, Michetti P, Hirt R, Perregaux C, Mekalanos JJ, Neutra MR. Role of transepithelial transport in triggering a mucosal immune response and in delivery of mucosal antibodies into secretions. In: Courtoy P, Gruenberg J, Mata LR, Marsh M van Deurs B. eds. *Endocytosis*. NATO ASI Series Vol. H62, Springer Verlag: Berlin Heidelberg, 1992; 363-366.

145. Amerongen HM, Weltzin R, Mack JA, Winner LS, Michetti P, Apter FM, Kraehenbuhl JP, Neutra MR. M Cell-Mediated Antigen Transport and Monoclonal IgA Antibodies for Mucosal Immune Protection. *Ann NY Acad Sci* 1992; 664: 18-26.
146. Weber B, Vouillamoz D, Schnegg J-F, Duroux Ph, Schwitzer W, Michetti P, Dorta G, Thorens J, Froelich F, Bretholz A, Fasel J, Frei A, Guyot J, Margalith D, Felley Ch, Gonvers J-J, Blum AL. Acquisitions thérapeutiques 1993: Gastro-entérologie, affections peptiques. *Méd & Hyg* 1994;52:160-171.
147. Phalipon A, Michetti P, Kaufmann M, Cavaillon JM, Huerre M, Kraehenbuhl JP, Sansonetti PJ. Protection against invasion of the mouse pulmonary epithelium by a monoclonal IgA directed against *Shigella flexneri* lipopolysaccharide. *Ann NY Acad Sci* 1994;730:356-358.
148. Michetti P, Haas R. Steps towards a vaccine. *Curr Opin Gastro* 1994;10 suppl:53-57.
149. Wiesel PH, Blum AL, Labenz J, Kreiss C, Michetti P. Acquisitions thérapeutiques 1994: Ulcère gastro-duodéal. *Méd & Hyg* 1995;53:165-172.
150. Corthésy-Theulaz I, Michetti P. Immunothérapie préventive et curative anti-Helicobacter. *La lettre de l'infectiologue*, 1995;10:146-148.
151. Ghiara P, Michetti P. Development of a vaccine. *Curr Opin Gastro* 1995;11 suppl: 52-56.
152. Michetti P. Immunisation against Helicobacter infections. In Price A, Malfertheiner P, Michetti P, eds. *Helicobacter pylori, an atlas*. Science Press, Oxford, UK 1996;12.1-12.6.
153. Michetti P, Wadström T, Kraehenbuhl JP, Lee A, Kreiss C, Blum AL. Frontiers in *Helicobacter pylori* research: pathogenesis, host response, vaccine development and new therapeutical approaches. *Eur J Gastroenterol.*, 1996;8:717-722.
154. Wiesel PH, Schneider R, Vouillamoz D, Blum AL, Michetti P. Acquisitions thérapeutiques 1995 - Ulcère gastro-duodéal. *Méd & Hyg* 1996;72:173-182.
155. Borovicka J, Michetti P. Oesophageal hypersensitivity. *Gut* 1996;39:147-148.
156. Corthésy-Theulaz I, Michetti P, Blum A, Kraehenbuhl JP. Vaccination against Helicobacter; current approach in the treatment of gastric ulcers. *Rev Med Suisse Romande* 1996;116:541-544.
157. Saldinger P, Michetti P. Changes in Immunologic Effector Responses after immunization for *H. pylori*. In Ernst PB, Michetti P, Smith PD, eds. *Immunobiology of H. pylori, from pathogenesis to Prevention*. Lippincott-Raven, Philadelphia-New York, USA 1997;287-296.
158. Michetti P. Les vaccins anti-Helicobacter. In Mégraud F, Lamouliatte H, eds. *Helicobacter pylori*, volume 2, Clinique, Traitement. *éditions Elsevier*, Paris, 1997;447-457.
159. Wiesel PH, Blum AL, Michetti P. Acquisitions thérapeutiques 1996 - Ulcère gastro-duodéal. *Méd & Hyg* 1997;55:167-172.
160. Michetti P. Vaccine against *Helicobacter pylori* : Fact or Fiction? *Gut* 1997;41:728-730.
161. Frossard JL, Michetti P. GI News 1: Incidence et rôle du virus de l'hépatite G dans l'hépatite aiguë non A-E ; Signification des petits adénomes détectés par sigmoidoscopie ; Prise en charge des patients dyspeptiques infectés par *H. pylori*. *Méd & Hyg* 1997;55:1196-1197.
162. Frossard JL, Michetti P. GI News 2: Oesophagite de reflux après élimination de *H. pylori* ; Thalidomide: une nouvelle ère thérapeutique? Traitement des ulcérations aphtoides oro-pharyngées et traitement des diarrhées chroniques causées par microsporidia. *Méd & Hyg* 1997;55:1515-1516.
163. Frossard JL, Michetti P. GI News 3: Histoire naturelle de l'hypertension portale après pose d'un TIPS ; Un modèle pronostique pour les patients avec cirrhose hépatique avancée ; Mesalanine orale ou par lavement pour la recto-colite ulcéro-hémorragique distale ; Vaccination contre les entérites dues aux rotavirus. *Méd & Hyg* 1997;55:2334-2337.

164. Kelly CP, Michetti P. *Helicobacter pylori* infection: Pathogenesis. *Curr Opin Gastro*, 1998;14:57-63.
165. Michetti P. Maladie de Crohn: Et pourtant il y a du nouveau! *Tribune Médicale* 1998;48:3.
166. Michetti P. Development of a vaccine against *Helicobacter pylori* infection. *Ital J Gastroenterol Hepatol* 1998;30:S339-S341.
167. Michetti P. Oral immunization against *H. pylori* - A future concept. *J Gastro* 1998;33 suppl 10:66-68.
168. Frossard JL, Michetti P. GI News 4: Anticorps anti-TNF dans la maladie de Crohn ; Enzymes pancréatiques comme traitement antalgique dans la pancréatite chronique ; Coût-bénéfice des antibiotiques dans la prophylaxie de la péritonite bactérienne spontanée. *Méd & Hyg* 1998;56:550-553.
169. Frossard JL, Michetti P. GI News 5: Hépatite A fulminante: Un risque élevé en cas d'hépatite C chronique ; Utilité du rapport ASAT/ALAT dans l'hépatite C chronique ; Le subsalicylate de bismuth dans la colite microscopique. *Méd & Hyg* 1998;56:1062-1065.
170. Frossard JL, Michetti P. GI News 6: Anti-inflammatoires et polypes coliques ; L'omeprazole et les ulcères sur anti-inflammatoires non stéroïdiens. *Méd & Hyg* 1998;56:1784-1786.
171. Frossard JL, Michetti P. GI News 7: Progrès dans la compréhension de la pancréatite chronique ; Détection d'ADN de *H. pylori* dans les mouches. Est-ce la découverte d'un vecteur de l'infection? ; La sigmoidoscopie comme triage avant colonoscopie. *Méd & Hyg* 1998;56:2345-2349.
172. Michetti P, Peppercorn MA. Medical therapy of specific clinical presentations of inflammatory bowel diseases. *Gastroenterol Clin North Am*, 1999; 28: 353-369.
173. Suerbaum S, Hur C, Josenhans C, Michetti P. Pathogenesis and virulence factors of *Helicobacter pylori*. *Curr Opin Gastro* 1999; 15:S11-S16.
174. Banerjee S, Michetti P. Strategies for developing a *Helicobacter pylori* vaccine. *Curr Opin Gastro* 1999; 15: 557-561.
175. Frossard JL, Michetti P. GI News 8: Pancréatite aiguë sévère : l'imipenem reste l'antibiotique de choix ; Budésônide et maladie de Crohn : une nouvelle donnée? ; Dyspepsie non-ulcéreuse et *Helicobacter pylori*. *Méd & Hyg* 1999;57:389-391.
176. Saldinger PF, Michetti P. GI News 9: Symptômes de reflux gastro-oesophagien et risque d'adénocarcinome de l'oesophage ; La prévention primaire de l'hémorragie sur varices oesophagiennes par ligature endoscopique ; Progression de l'incidence du cancer hépatocellulaire ; Evolution de la colite lymphocytaire. *Méd & Hyg* 1999;57:1106-1108.
177. Saldinger PF, Michetti P. GI News 10: Anticorps anti-TNF pour le traitement des fistules dans la maladie de Crohn ; Nouveaux traitements pour la fissure anale ; L'acide ursodeoxycholique à long terme dans la cirrhose biliaire primitive ; Un nouveau test pour le diagnostic non-invasif de l'infection active par *Helicobacter pylori*. *Méd & Hyg* 1999;57:1597-1599.
178. Saldinger PF, Michetti P. GI News 11: Proctocolectomie restaurative par J-Pouch (PR) dans la colite ulcéreuse distale ; Perfusion d'albumine dans la cirrhose avec péritonite bactérienne spontanée ; Le cholédoque se dilate-t-il après cholécystectomie? ; Dyspepsie ulcéreuse – endoscopie ou "test and treat"? *Méd & Hyg* 1999;57:2430-2434.
179. Michetti P. The inflammatory activity in *Helicobacter pylori* infection is predominantly organism related. In Hunt and Tytgat eds. *Helicobacter pylori* 2000. *Kluwer Academic Press, UK* 2000:197-202.
180. Michetti P. Intestinal pathogens or IBD, same T-cell response. *Inflam Bowel Diseases* 2000 ;6 :63-64.
181. Michetti P. Future developments in therapy. *Curr Opin Gastro* 2000; 16:S1-S4.
182. Corthésy-Theulaz I, Michetti P. What's new in anti-*Helicobacter pylori* vaccination? *Gastroenterol Clin Biol*. 2000;24:1186-1190.

183. Michetti P. Vaccination contre *Helicobacter pylori*. *La Revue du Praticien* 2000 ;50 :1444.
184. Michetti P, Peppercorn MA. Use of antibiotics and other anti-infectious agents in ulcerative colitis. In Bayless TM, Hanauer SB, eds. *Advanced therapy of Inflammatory Bowel Disease*, 2nd ed. *BC Decker Inc. Publisher, Canada. In press.*
185. Kelly CP, Michetti P. Inflammatory Bowel Disease. Noble J, editor. *Textbook of Primary Care Medicine*. *Mosby, Inc., St Louis, Missouri*, 2001, p. 983-990.
186. Banerjee S, Michetti P. Vaccine development against *Helicobacter pylori*. In Achtman M, Suerbaum S, eds. *Helicobacter pylori : Molecular and Cellular Biology*. *Horizon Press, UK*. 2001, p. 263-274.
187. Alsahli M, Farrell RJ, Michetti P. Vaccines: an ongoing promise? *Dig Dis*. 2001;19(2):148-57
188. Keller WC, Michetti P. Vaccination against *Helicobacter pylori* - an old companion of man. *Expert Opin Biol Ther*. 2001 Sep;1(5):795-802.
189. Alsahli M, Michetti P. Lactobacilli for the management of *Helicobacter pylori*. *Nutrition* 2001;17:268-9.
190. Felley C, Michetti P. Ulcerative colitis. *Rev Med Suisse Romande*. 2002;122(9):441-4.
191. Givel JC, Aellen S, Moubayed H, Michetti P, Dorta G, Popescu R. Colorectal cancer: curative therapy and follow-up. *Rev Med Suisse Romande*. 2002;122(9):417-9.
192. Moubayed H, Popescu R, Aellen S, Givel JC, Michetti P, Dorta G. Screening and prevention of colorectal cancer. *Rev Med Suisse Romande*. 2002;122(9):413-6.
193. Suerbaum S and Michetti P. *Helicobacter pylori* Infection. *New Engl J Med* 2002; 347:1175-86.
194. Michetti P, Oneta CM, Seibold F. Treatment of inflammatory bowel disease and its complications (Part I). *Forum Med Suisse* 2002;46:1091-95.
195. Ortner MA, Dorta G, Blum AL, Michetti P. Endoscopic interventions for preneoplastic and neoplastic lesions: mucosectomy, argon plasma coagulation, and photodynamic therapy. *Dig Dis*. 2002;20(2):167-72.
196. Felley C, Michetti P. Probiotics and *Helicobacter pylori*. *Best Pract Res Clin Gastroenterol*. 2003 Oct;17(5):785-91.
197. Michetti P, Svennerholm AM. *Helicobacter pylori*- inflammation, immunity and vaccines. *Helicobacter*. 2003;8 Suppl 1:31-5.
198. Felley C, Michetti P. Engineered lymphocytes to treat dinitrobenzene sulphonic acid colitis in mice. *Eur J Gastroenterol Hepatol*. 2003 Dec;15(12):1253-5.
199. Del Giudice G, Michetti P. Inflammation, Immunity and Vaccines for *Helicobacter pylori*. *Helicobacter*. 2004;9 Suppl 1:23-8.
200. Michetti P. Experimental *Helicobacter pylori* infection in humans: a multifaceted challenge. *Gut*. 2004 Sep;53(9):1220-1.
201. Felley C, Michetti P. Safety of Infliximab in Patients Suffering from Inflammatory Bowel Disease. *Digestion*. 2004;70(1):1-2.
202. Michetti P, Oneta CM, Seibold F. Treatment of inflammatory bowel disease and its complications (Part II). *Forum Med Suisse*, in press.
203. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: The treatment of irritable bowel syndrome. *Aliment Pharmacol Ther*. 2004;20:1253-69.
204. Felley C, Guyot J, Hess J, Mottet C, Delarive J, Michetti P. Inflammatory bowel diseases. *Rev Med Suisse*. 2005;1(3):218-20, 223-7.

205. Caprilli R, Michetti P. The European Panel on the Appropriateness of Crohn's Disease Therapy. *Digestion* 2005;71:6-7
206. Juillerat P, Felley C, Mottet C, Froehlich F, Vader JP, Burnand B, Gonvers JJ, Michetti P. Drug Safety in the Treatment of Crohn's Disease. *Digestion* 2005;71:8-12.
207. Michetti P, Juillerat P, Mottet C, Gonvers JJ, Burnand B, Vader JP, Froehlich F, Felley C. Therapy of Mild to Moderate Luminal Crohn's Disease. *Digestion* 2005;71:13-18.
208. Michetti P, Mottet C, Juillerat P, Felley C, Vader JP, Burnand B, Gonvers JJ, Froehlich F. Severe and Steroid-Resistant Crohn's Disease. *Digestion* 2005;71:19-25.
209. Felley C, Mottet C, Juillerat P, Froehlich F, Burnand B, Vader JP, Michetti P, Gonvers JJ. Fistulizing Crohn's Disease. *Digestion* 2005;71:26-28.
210. Froehlich F, Juillerat P, Mottet C, Felley C, Vader JP, Burnand B, Gonvers JJ, Michetti P. Obstructive Fibrostenotic Crohn's Disease. *Digestion* 2005;71:29-30.
211. Juillerat P, Mottet C, Froehlich F, Felley C, Vader JP, Burnand B, Gonvers JJ, Michetti P. Extraintestinal Manifestations of Crohn's Disease. *Digestion* 2005;71:31-36.
212. Mottet C, Juillerat P, Gonvers JJ, Michetti P, Burnand B, Vader JP, Felley C, Froehlich F. Treatment of Gastroduodenal Crohn's Disease. *Digestion* 2005;71:37-40.
213. Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F. Maintenance of Remission in Crohn's Disease. *Digestion* 2005;71:41-48.
214. Froehlich F, Juillerat P, Felley C, Mottet C, Vader JP, Burnand B, Michetti P, Gonvers JJ. Treatment of Postoperative Crohn's Diseases. *Digestion* 2005;71:49-53.
215. Mottet C, Juillerat P, Gonvers JJ, Froehlich F, Burnand B, Vader JP, Michetti P, Felley C. Pregnancy and Crohn's Disease. *Digestion* 2005;71:54-61.
216. Kuipers EJ, Michetti P. Bacteria and mucosal inflammation of the gut: lessons from *Helicobacter pylori*. *Helicobacter*. 2005;10 Suppl 1:66-70.
217. Michetti P. What is the impact of polypharmacy in patients with Crohn's disease? *Nat Clin Pract Gastroenterol Hepatol*. 2005;2:448-9.
218. Velin D, Michetti P. Immunology of *Helicobacter pylori* Infection. *Digestion*. 2006 Jun 20;73(2-3):116-123.
219. Felley C, Guyot J, Hess J, Mottet C, Delarive J, Michetti P. Inflammatory diseases of the intestines. *Rev Med Suisse*. 2006;2:191-4, 196-8, 201-3.
220. Michetti P. A mix for progress. *Rev Med Suisse*. 2006;2:179-80.
221. Bauerfeind P, Beglinger C, Beltinger J, Braegger C, Eigenmann F, Fried M, Guyot J, Hurlimann R, Michetti P, Seibold F, Straumann A. Infliximab--practical guidelines for the treatment of Crohn's disease. *Rev Med Suisse*. 2006;2:1807-15.
222. Felley C, Mottet C, Hess J, Juillerat P, Guyot J, Delarive J, Michetti P. Main therapeutic advances in IBD. *Rev Med Suisse*. 2007;3:201-2, 204-6, 208-14.
223. Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. *Dermatology*. 2007;215:245-51.
224. Fontana M, Giostra E, Pilon N, Michetti P, Mentha G, Pascual M, Moradpour D. Liver transplantation: new organ allocation system in Switzerland. *Rev Med Suisse*. 2008;4:221-3.
225. Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. Drug safety in Crohn's disease therapy. *Digestion*. 2007;76:161-8.
226. Mottet C, Juillerat P, Pittet V, Gonvers JJ, Froehlich F, Vader JP, Michetti P, Felley C. Pregnancy and breastfeeding in patients with Crohn's disease. *Digestion*. 2007;76:149-60.

227. Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, Vader JP, Michetti P. Extraintestinal manifestations of Crohn's disease. *Digestion*. 2007;76:141-8.
228. Mottet C, Juillerat P, Pittet V, Gonvers JJ, Michetti P, Vader JP, Felley C, Froehlich F. Upper gastrointestinal Crohn's disease. *Digestion*. 2007;76(2):136-40.
229. Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ. Maintenance of surgically induced remission of Crohn's disease. *Digestion*. 2007;76(2):130-5. Epub 2008 Feb 7.
230. Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F. Maintenance of medically induced remission of Crohn's disease. *Digestion*. 2007;76:116-29.
231. Froehlich F, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Gonvers JJ, Michetti P. Fibrostenotic Crohn's disease. *Digestion*. 2007;76:113-5.
232. Felley C, Mottet C, Juillerat P, Pittet V, Froehlich F, Vader JP, Michetti P, Gonvers JJ. Fistulizing Crohn's disease. *Digestion*. 2007;76:109-12.
233. Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader JP, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease. *Digestion*. 2007;76:99-108.
234. Michetti P, Juillerat P, Mottet C, Pittet V, Gonvers JJ, Vader JP, Froehlich F, Felley C. Mild-to-moderate active luminal Crohn's disease. *Digestion*. 2007;76:92-8.
235. Juillerat P, Froehlich F, Felley C, Pittet V, Mottet C, Gonvers JJ, Michetti P, Vader JP. EPACK II: project and methods. *Digestion*. 2007;76:84-91. Epub 2008 Feb 7.
236. Maerten P, Ortner M, Michetti P, Dorta G. Wireless capsule pH monitoring: does it fulfil all expectations? *Digestion*. 2007;76: 235-40.
237. Michetti P. Agents anti-TNF, la classe s'agrandit pour le traitement de la maladie de Crohn. *Rev Med Suisse* 2008;4:187-188.
238. Felley C, Mottet C, Maillard MH, Hess J, Delarive J, Michetti P. Main therapeutic advances in IBD in 2007. *Rev Med Suisse*. 2008; 4(141):200, 202-4.
239. Fontana M, Giostra E, Pilon N, Michetti P, Mentha G, Pascual M, Moradpour D. Liver transplantation: new organ allocation system in Switzerland. *Rev Med Suisse*. 2008; 4(141):221-3.
240. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, Hoffmann JO, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S, Mitchell R, Panes J, Soderholm J, Vucelic B, Stange E, for the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: Special Situations. *Journal of Crohn's and Colitis* 2008; 2: 63-92.
241. Felley C, Mottet C, Hess J, Maillard MH, Delarive J, Michetti P. Main therapeutic advances in IBD in 2008. *Rev Med Suisse*. 2009; 5(187):185-6, 188-90, 192-4.
242. Michetti P. Fistula treatment: the unresolved challenge. *Dig Dis*. 2009;27(3):387-93.
243. Velin D, Michetti P. Advances in vaccination against *Helicobacter pylori*. *Expert Rev Gastroenterol Hepatol*. 2010;4:157-66.
244. Michetti P. [Inflammatory bowel disease: what is the physician's role?]. *Rev Med Suisse* 2011;7:222.
245. Manz M., Michetti P., Seibold F., Rogler G., Beglinger C. Treatment algorithm for moderate to severe ulcerative colitis., *Swiss Med Wkly*. 2011 Jun 27;141:w13235.
246. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., Chowers Y., D'Haens G., Feagan B.G., Hibi T., Hommes D.W., Irvine E.J., Kamm M.A., Loftus E.V., Louis E., Michetti P., Munkholm P., Oresland T., Panés J., Peyrin-Biroulet L., Reinisch W., Sands B.E., Schoelmerich J., Schreiber S., Tilg H., Travis S., van Assche G., Vecchi M., Mary J.Y., Colombel J.F., Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. *Inflammatory Bowel Diseases* 2011;17:1415-1422.

247. Reinisch W, Van Assche G, Befrits R, Connell W, D'Haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg MS, Sorrentino D, van der Woude CJ, Vermeire S, Panes J. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. *J Crohns Colitis*. 2012;6:248-58.
248. Feagan BG, Lémann M, Befrits R, Connell W, D'Haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg M, Sorrentino D, van der Woude CJ, Vermeire S, Rutgeerts P. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. *Inflamm Bowel Dis*. 2012;18:152-60.
249. Burri E, Beglinger C, Biedermann L, Michetti P, Nydegger A, Schoepfer A, Seibold F, Vavricka S, Rogler G. Diagnostischer Nutzen von Calprotectin im klinischen Alltag. *Swiss Medical Forum* 2016;16(3):68-73.
250. Moschouri E, Hessler R, Pittet V, Velin D, Conrad C, Hahnloser D, Gié O, Michetti P, Schoepfer AM, Maillard MH. [Management of ulcerative colitis in 2017]. *Rev Med Suisse*. 2017 Aug 30;13(572):1480-1486.
251. Greuter T, Maillard MH, Juillerat P, Michetti P, Seibold F, Mottet C, Zahnd N, Sauter B, Schoepfer AM, Rogler G, Vavricka SR; on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. *Digestion*. 2019 Aug 28:1-9. doi: 10.1159/000501930.
252. Burri E, Juillerat P, Maillard MH, Manz M, Michetti P, Mottet C, Rogler G, Zahnd N, Vavricka S. Position statement on the use of biosimilars in inflammatory bowel disease. *Swiss Med Wkly*. 2019 Dec 2;149:w20148. doi: 10.4414/smw.2019.20148
253. Michetti P. Quatre atouts à ramener à votre cabinet sur les maladies inflammatoires de l'intestin. *Rev Med Suisse*. 2020 Jan 29;16(679):212-213.
254. Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F; on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Treatment Algorithms for Crohn's Disease. *Digestion*. 2020;101 Suppl 1:43-57. doi: 10.1159/000506364. Epub 2020 Mar 13.
255. Schreiner P, Mueller NJ, Fehr J, Maillard MH, Brand S, Michetti P, Schoepfer A, Restellini S, Vulliemoz M, Vavricka SR, Juillerat P, Rogler G, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. *J Crohns Colitis*. 2020 Jun 27;jjaa132. doi: 10.1093/ecco-jcc/jjaa132. Online ahead of print.
256. Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P; on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. *Digestion*. 2020;101 Suppl 1:16-26. doi: 10.1159/000506898. Epub 2020 Jul 31